Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Cordlife Group ( (SG:P8A) ).
Cordlife Group Limited has issued a clarification regarding inaccuracies in recent media reports about its operations. The company highlighted errors in the media’s portrayal of the Ministry of Health’s notice to suspend its cord blood banking service license and the number of cord blood units affected by alleged process failures. Cordlife is addressing these inaccuracies and has been granted an extension by the Ministry of Health to provide written representations concerning the notice.
More about Cordlife Group
Cordlife Group Limited, registered in Singapore, operates in the healthcare industry, focusing on cord blood and human tissue banking services. The company is known for its cord blood banking service license, which is periodically renewed by the Ministry of Health.
Average Trading Volume: 47,731
Technical Sentiment Signal: Strong Sell
Current Market Cap: S$41.36M
See more data about P8A stock on TipRanks’ Stock Analysis page.